mhurhangee/patent-ind-claim-en huggingface dataset:
An antigen binding protein comprising at least one CD3 binding site, wherein the CD3 binding site comprises: (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4; or (c) a variable heavy chain domain (VH) having sequence identity of at least 95% compared to the VH as depicted in SEQ ID NO:8, wherein the amino acid residue at position 111 is Y or H, and a variable light chain domain (VL) having sequence identity of at least 95% compared to the VL as depicted in SEQ ID NO:3, wherein the amino acid residue at position 49 is G or A; or (d) a variable heavy chain domain (VH) incorporating 1 to 5 conserved amino acid substitutions compared to the VH as depicted in SEQ ID NO:8, wherein the amino acid residue at position 111 is Y or H, and a variable light chain domain (VL) incorporating 1 to 5 conserved amino acid substitutions compared to the VL as depicted in SEQ ID NO:3, wherein the amino acid residue at position 49 is G or A; and the antigen binding protein of (a), (b), (c) or (d) is not a bispecific binding protein that specifically binds to human CD33 and human CD3, wherein the CD3 binding site comprises an anti-CD3 variable light chain domain selected from the group consisting of SEQ ID NOs:1-3 and an anti-CD3 variable heavy chain domain selected from the group consisting of SEQ ID NOs:6-8. (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4; or (c) a variable heavy chain domain (VH) having sequence identity of at least 95% compared to the VH as depicted in SEQ ID NO:8, wherein the amino acid residue at position 111 is Y or H, and a variable light chain domain (VL) having sequence identity of at least 95% compared to the VL as depicted in SEQ ID NO:3, wherein the amino acid residue at position 49 is G or A; or (d) a variable heavy chain domain (VH) incorporating 1 to 5 conserved amino acid substitutions compared to the VH as depicted in SEQ ID NO:8, wherein the amino acid residue at position 111 is Y or H, and a variable light chain domain (VL) incorporating 1 to 5 conserved amino acid substitutions compared to the VL as depicted in SEQ ID NO:3, wherein the amino acid residue at position 49 is G or A; and
A gasoline engine exhaust gas treatment system comprising: an ammonia generating and hydrocarbon oxidation catalyst comprising a refractory metal oxide support, a platinum component, and a palladium component, wherein the platinum component and the palladium components are present in a platinum to palladium (Pt/Pd) ratio of 6/1 to 10/1, and wherein the ammonia generating and hydrocarbon oxidation catalyst contains less than 0.1 wt. % of ceria and less than 0.1 wt.-% of a NOx storage component; a three-way conversion (TWC) catalyst; and an ammonia selective catalytic reduction (SCR) catalyst downstream of the three-way conversion catalyst. an ammonia generating and hydrocarbon oxidation catalyst comprising a refractory metal oxide support, a platinum component, and a palladium component, wherein the platinum component and the palladium components are present in a platinum to palladium (Pt/Pd) ratio of 6/1 to 10/1, and wherein the ammonia generating and hydrocarbon oxidation catalyst contains less than 0.1 wt. % of ceria and less than 0.1 wt.-% of a NOx storage component; a three-way conversion (TWC) catalyst; and an ammonia selective catalytic reduction (SCR) catalyst downstream of the three-way conversion catalyst.
A system for estimating friction, the system including: a contact surface comprising a plurality of protrusions extending from a base surface , the contact surface further including a first contact surface region and a second contact surface region , the first contact surface region being configured to resist slip less than the second contact surface region ; and a sensor arrangement configured for detecting displacement of at least three of the plurality of protrusions in three different dimensions to measure a three-dimensional force applied to the at least three of the plurality of protrusions at a moment of slippage of the first contact surface region . a contact surface comprising a plurality of protrusions extending from a base surface , the contact surface further including a first contact surface region and a second contact surface region , the first contact surface region being configured to resist slip less than the second contact surface region ; and a sensor arrangement configured for detecting displacement of at least three of the plurality of protrusions in three different dimensions to measure a three-dimensional force applied to the at least three of the plurality of protrusions at a moment of slippage of the first contact surface region .
Biocide mixture comprising the biocides a) azoxystrobin (methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate) and b) IPBC (3-iodopropynyl N-butylcarbamate), the weight ratio of components a) to b) being from 6:1-1:6, preferably from 1.8:1-1:6, in particular from 1.5:1-1:6. a) azoxystrobin (methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate) and b) IPBC (3-iodopropynyl N-butylcarbamate),
Arrangement with two or more layered slabs of natural stone, artificial stone such as concrete or resin-bonded stone flours, glass or ceramic - hereinafter called stone slab or slabs - wherein the overall arrangement of the stone slabs is mechanically stabilised over the cross-section of the overall structure by stabilising fibre fabric layers against exceeding the permissible tensile elongation, wherein a cut-out is located under the surface of the upper stone layer, which breaks through the stabilising fibre layer and which extends to just below the surface of the upper stone layer and within the cavity of which there is an induction coil for the inductive heating of magnetisable induction dishes, characterised in that the stiffness of the stone geometry below the tension-stable fibre layer is greater than the stiffness of the geometry of the upper cover layer which forms the surface and in that the fibres consist of carbon, glass or stone fibres.
A method for implementing a multi-qubit gate using an ion trap , comprising: providing ions in the ion trap to each be used as a separate qubit, each ion having three energy levels ; bringing a motional mode to a ground state of motion with the ions in the ion trap , the motional mode being different from a center-of-mass, CoM, mode and having a spatial frequency profile based on a spacing of the ions in the ion trap causing the motional mode to have a low-heating rate; performing a Cirac and Zoller, CZ, protocol using the motional mode as a motional state of the CZ protocol and one of the energy levels as an auxiliary state of the CZ protocol ; and following the performing of the CZ protocol, directly implementing the multi-qubit gate as a single native operation using the prepared ions in the ion trap , the multi-qubit gate having three or more qubits. providing ions in the ion trap to each be used as a separate qubit, each ion having three energy levels ; bringing a motional mode to a ground state of motion with the ions in the ion trap , the motional mode being different from a center-of-mass, CoM, mode and having a spatial frequency profile based on a spacing of the ions in the ion trap causing the motional mode to have a low-heating rate; performing a Cirac and Zoller, CZ, protocol using the motional mode as a motional state of the CZ protocol and one of the energy levels as an auxiliary state of the CZ protocol ; and following the performing of the CZ protocol, directly implementing the multi-qubit gate as a single native operation using the prepared ions in the ion trap , the multi-qubit gate having three or more qubits.
A rollbar chain for a continuous press , particularly for producing wood based boards, composite boards or composite components, wherein the rollbar chain is realized in the form of a plate-link chain , on which rollbars can be fastened by means of rollbar bearing bolts , wherein the plate-link chain has link plates that are connected by means of chain bolts , and wherein the link plates have elongate holes , which extend in the chain circulating direction and into which the rollbar bearing bolts can be inserted, characterized in that the chain bolts are at least sectionally provided with a self-lubricating coating, wherein the self-lubricating coating is either produced on the basis of carbon and realized in the form of a coating on the basis of tungsten carbide or wherein the coating is formed of molybdenum sulfide. wherein the rollbar chain is realized in the form of a plate-link chain , on which rollbars can be fastened by means of rollbar bearing bolts , wherein the plate-link chain has link plates that are connected by means of chain bolts , and wherein the link plates have elongate holes , which extend in the chain circulating direction and into which the rollbar bearing bolts can be inserted, characterized in that the chain bolts are at least sectionally provided with a self-lubricating coating, wherein the self-lubricating coating is either produced on the basis of carbon and realized in the form of a coating on the basis of tungsten carbide or wherein the coating is formed of molybdenum sulfide.
A recombinant chimeric nucleic acid molecule comprising a nucleic acid sequence encoding a dual transit peptide operably linked to a heterologous nucleic acid sequence encoding a polypeptide of interest, wherein said dual transit peptide is from the genus Amaranthus which comprises a sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4, and wherein said heterologous polypeptide of interest is from a prokaryote, which, when overexpressed in a plant, confers herbicide tolerance to said plant, and wherein said polypeptide has PPO activity and confers tolerance to PPO-inhibiting herbicides. wherein said dual transit peptide is from the genus Amaranthus which comprises a sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4, and wherein said heterologous polypeptide of interest is from a prokaryote, which, when overexpressed in a plant, confers herbicide tolerance to said plant, and wherein said polypeptide has PPO activity and confers tolerance to PPO-inhibiting herbicides.
A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of: and
A unit dose capsule for treatment of a substrate, the capsule comprising three compartments containing a substrate treatment composition, wherein: the capsule is formed from two sheets of water-soluble film, the two sheets of film being sealed together forming a sealing web lying on a sealing plane, the sealing web comprising a peripheral sealing skirt , inter-compartment sealing webs between compartments thereby separating the compartments from one another and a central sealing web , wherein the compartments have an average surface extention ratio in the range of 1.5 to 3, the surface extension ratio is the surface area of the film above the sealing plane to surface area of footprint the compartments located in the sealing plane.
A method, performed by an apparatus , for scheduling user terminals for downlink transmission in a communication network, the method comprising: determining a duration of a discontinuous reception cycle for a user terminal , wherein the beginning of the cycle triggers a first active period during which the user terminal is in an active mode; and determining an interval between periodic channel quality indicator reports for the user terminal , aligning the discontinuous reception cycle with the interval between the periodic channel quality indicator reports such that the periodic channel quality indicator is transmitted within the first active period of the discontinuous reception cycle ; receiving the periodic channel quality indicator during the first active period of the discontinuous reception cycle , thus obtaining an up-to-date channel quality indicator for the discontinuous reception cycle ; and characterized by the method further comprising: scheduling the user terminals for downlink transmission by prioritizing the user terminals in the downlink transmission scheduling based on the quality of the available channel quality indicators from the user terminals , wherein the quality of the channel quality indicator is determined by the type of the channel quality indicator obtained from the user terminals . determining a duration of a discontinuous reception cycle for a user terminal , wherein the beginning of the cycle triggers a first active period during which the user terminal is in an active mode; and determining an interval between periodic channel quality indicator reports for the user terminal , aligning the discontinuous reception cycle with the interval between the periodic channel quality indicator reports such that the periodic channel quality indicator is transmitted within the first active period of the discontinuous reception cycle ; receiving the periodic channel quality indicator during the first active period of the discontinuous reception cycle , thus obtaining an up-to-date channel quality indicator for the discontinuous reception cycle ; and characterized by the method further comprising: scheduling the user terminals for downlink transmission by prioritizing the user terminals in the downlink transmission scheduling based on the quality of the available channel quality indicators from the user terminals , wherein the quality of the channel quality indicator is determined by the type of the channel quality indicator obtained from the user terminals .
A method of blood fractionation comprising: a) centrifuging whole blood in a first syringe having a top coupling element and a bottom coupling element , wherein the whole blood fractionates into a platelet poor plasma layer, a buffy layer, and an erythrocyte layer within the syringe; b) removing at least a portion of the platelet poor plasma layer from the top coupling element of the first syringe ; c) attaching a bottom coupling element of a second syringe or second container to the top coupling element of the first syringe ; d) drawing any of the platelet poor plasma layer, the buffy layer, and optionally part of the erythrocyte layer into the second syringe or second container ; and e) centrifuging the second syringe or second container wherein the any of the platelet poor plasma layer, the buffy layer, and the erythrocyte layer fractionates into a platelet rich plasma layer and an erythrocyte layer. a) centrifuging whole blood in a first syringe having a top coupling element and a bottom coupling element , wherein the whole blood fractionates into a platelet poor plasma layer, a buffy layer, and an erythrocyte layer within the syringe; b) removing at least a portion of the platelet poor plasma layer from the top coupling element of the first syringe ; c) attaching a bottom coupling element of a second syringe or second container to the top coupling element of the first syringe ; d) drawing any of the platelet poor plasma layer, the buffy layer, and optionally part of the erythrocyte layer into the second syringe or second container ; and e) centrifuging the second syringe or second container wherein the any of the platelet poor plasma layer, the buffy layer, and the erythrocyte layer fractionates into a platelet rich plasma layer and an erythrocyte layer.
A pharmaceutical composition deliverable from a metered dose inhaler, the pharmaceutical composition comprising: a propellant of pharmaceutical grade -1,3,3,3-Tetrafluoro-1-propene (HFO-1234ze(E)) having a purity of at least 99.90%; a plurality of one or more species of active agent particles; and a plurality of phospholipid particles comprising perforated microstructures; wherein the one or more active agents are selected from a long-acting muscarinic antagonist (LAMA), a long-acting β2-agonists (LABA), a short-acting beta-agonists (SABA), an inhaled corticosteroid (ICS), and a non-corticosteroid anti-inflammatory agent, wherein the pharmaceutical composition comprises: (i) a plurality of budesonide particles, and a plurality of albuterol particles; (ii) a plurality of glycopyrrolate particles, and a plurality of formoterol particles; or (iii) a plurality of budesonide particles, and a plurality of formoterol particles. a propellant of pharmaceutical grade -1,3,3,3-Tetrafluoro-1-propene (HFO-1234ze(E)) having a purity of at least 99.90%; a plurality of one or more species of active agent particles; and a plurality of phospholipid particles comprising perforated microstructures; wherein the one or more active agents are selected from a long-acting muscarinic antagonist (LAMA), a long-acting β2-agonists (LABA), a short-acting beta-agonists (SABA), an inhaled corticosteroid (ICS), and a non-corticosteroid anti-inflammatory agent, wherein the pharmaceutical composition comprises: (i) a plurality of budesonide particles, and a plurality of albuterol particles; (ii) a plurality of glycopyrrolate particles, and a plurality of formoterol particles; or (iii) a plurality of budesonide particles, and a plurality of formoterol particles. (i) a plurality of budesonide particles, and a plurality of albuterol particles; (ii) a plurality of glycopyrrolate particles, and a plurality of formoterol particles; or (iii) a plurality of budesonide particles, and a plurality of formoterol particles.
A bioreactor for the generation of cellularized medical implants characterized in that it comprises an external watertight unicompartmented or multicompartmented chamber containing in its interior one or more matrices , these interior matrices and the bioreactor's external chamber being simultaneously manufactured through a process of rapid prototyping; wherein the external chamber comprises a shape adapted to the implant shape to be cellularized (internal matrix), and in that it allows the implants to be removed from the interior of the bioreactor by cutting the external chamber in locations comprising grooves right before implantation, enabling the sterility of the implant.
A data transmission method, comprising: before an RRC connection is established, sending a data message carrying state transition data to a network side device; wherein the state transition data is used to indicate whether uplink data to be transmitted supports a data transmission mode without state transition; wherein the state transition data includes a determination condition of whether or not to support the data transmission mode in which the state transition is not performed, or a determination result of the determination condition; the state transition means changing from disestablishment of the RRC connection to establishment of the RRC connection; receiving a response message returned by the network side device in response to the data message, wherein a data transmission indication is comprised in the response message; wherein the data transmission indication is used to indicate transmitting or non-transmitting the uplink data to be transmitted without the state transition; when the data transmission indication indicates transmitting the uplink data to be transmitted without the state transition, sending an uplink data packet to the network side device; when the data transmission indication indicates non-transmitting the uplink data to be transmitted without the state transition, establishing an RRC connection. before an RRC connection is established, sending a data message carrying state transition data to a network side device; wherein the state transition data is used to indicate whether uplink data to be transmitted supports a data transmission mode without state transition; wherein the state transition data includes a determination condition of whether or not to support the data transmission mode in which the state transition is not performed, or a determination result of the determination condition; the state transition means changing from disestablishment of the RRC connection to establishment of the RRC connection; receiving a response message returned by the network side device in response to the data message, wherein a data transmission indication is comprised in the response message; wherein the data transmission indication is used to indicate transmitting or non-transmitting the uplink data to be transmitted without the state transition; when the data transmission indication indicates transmitting the uplink data to be transmitted without the state transition, sending an uplink data packet to the network side device; when the data transmission indication indicates non-transmitting the uplink data to be transmitted without the state transition, establishing an RRC connection.
Method for the removal of polyvalent cations from mono ethylene glycol, comprising the steps of: a) providing a feed of aqueous mono ethylene glycol comprising dissolved carbon dioxide and salts of divalent cations, b) heating the aqueous mono ethylene glycol to 60 - 120°C to produce a heated mixture, causing precipitation of at least part of the salts and release of at least part of the dissolved carbon dioxide, c) separation of released carbon dioxide from the mono ethylene glycol in a flash separator, d) distillation of at least part of the water from the heated mixture in a reboiler, to yield hot dewatered mono ethylene glycol, wherein the temperature of the liquid in the distillation phase is 120 - 150°C, wherein a first part of the hot dewatered mono ethylene glycol which comprises particles of salts of divalent cations is led back to the aqueous mono ethylene glycol supplied in step a) to provide at least part of the heat for heating the aqueous mono ethylene glycol in step b), and wherein separation of at least part of the precipitated salts from the mono ethylene glycol is performed on a second part of the hot dewatered mono ethylene glycol that is not led back to the feed. a) providing a feed of aqueous mono ethylene glycol comprising dissolved carbon dioxide and salts of divalent cations, b) heating the aqueous mono ethylene glycol to 60 - 120°C to produce a heated mixture, causing precipitation of at least part of the salts and release of at least part of the dissolved carbon dioxide, c) separation of released carbon dioxide from the mono ethylene glycol in a flash separator, d) distillation of at least part of the water from the heated mixture in a reboiler, to yield hot dewatered mono ethylene glycol, wherein the temperature of the liquid in the distillation phase is 120 - 150°C,